I maintain a hold rating on PPH due to attractive valuation but weak technical momentum and underperformance versus the S&P 500. Eli Lilly and Johnson & Johnson, PPH’s largest holdings, are facing ...
The VanEck Pharmaceutical ETF has shown strong performance but faces near-term downside risks, prompting a rating downgrade from buy to hold. PPH's valuation has increased significantly, with a high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback